See more : Thai Polycons Public Company Limited (TPOLY.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Greenyn Biotechnology Co., Ltd (6846.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Greenyn Biotechnology Co., Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- NÜRNBERGER Beteiligungs-AG (NBG6.DE) Income Statement Analysis – Financial Results
- NutriPure Beverages, Inc. (NBVG) Income Statement Analysis – Financial Results
- Larvotto Resources Limited (LRV.AX) Income Statement Analysis – Financial Results
- Jiangsu Lianfa Textile Co.,Ltd (002394.SZ) Income Statement Analysis – Financial Results
- Serma Group Société anonyme (ALSER.PA) Income Statement Analysis – Financial Results
Greenyn Biotechnology Co., Ltd (6846.TWO)
About Greenyn Biotechnology Co., Ltd
Greenyn Biotechnology Co., Ltd, a dietary supplement company, develops, manufactures, and sells health products in Taiwan and internationally. The company offers proprietary ingredients, such as Insumate, a bitter melon extract; Antromax, an antrodia cinnamomea; and Zymologist 101 Phyto fermented drink. It also provides functional formulas for youth and beauty series, digestive health series, brain health series, body regulation series, throat moistening series, hair care series, clear eye series, colorful lifestyle series, joint health series, nutritional supplement series, energy supplement series, immune modulation series, low burden series, sleep aid series, body curve series, circulation series, man power series, women's intimate health series, and mature woman series. In addition, the company offers customization, ODM, dosage, and application services. Greenyn Biotechnology Co., Ltd was founded in 2012 and is based in Taichung, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 800.51M | 705.31M | 693.77M | 662.56M | 0.00 |
| Cost of Revenue | 408.05M | 334.38M | 335.75M | 323.65M | 0.00 |
| Gross Profit | 392.46M | 370.93M | 358.02M | 338.91M | 0.00 |
| Gross Profit Ratio | 49.03% | 52.59% | 51.61% | 51.15% | 0.00% |
| Research & Development | 56.25M | 57.43M | 52.46M | 32.39M | 0.00 |
| General & Administrative | 87.53M | 78.94M | 77.97M | 82.58M | 0.00 |
| Selling & Marketing | 87.84M | 67.88M | 58.46M | 64.30M | 0.00 |
| SG&A | 175.36M | 146.81M | 136.43M | 146.88M | 0.00 |
| Other Expenses | 0.00 | 17.36M | 974.00K | -1.04M | 129.70M |
| Operating Expenses | 220.40M | 204.24M | 188.89M | 179.26M | 129.70M |
| Cost & Expenses | 640.69M | 538.62M | 524.64M | 502.91M | 129.70M |
| Interest Income | 5.32M | 1.21M | 290.00K | 268.00K | 185.00K |
| Interest Expense | 1.65M | 1.25M | 1.37M | 1.75M | 3.17M |
| Depreciation & Amortization | 24.92M | 25.14M | 23.28M | 28.67M | 0.00 |
| EBITDA | 192.40M | 210.40M | 193.67M | 187.54M | 160.69M |
| EBITDA Ratio | 24.03% | 29.83% | 27.92% | 28.31% | 0.00% |
| Operating Income | 159.82M | 185.26M | 170.39M | 159.65M | 129.70M |
| Operating Income Ratio | 19.96% | 26.27% | 24.56% | 24.10% | 0.00% |
| Total Other Income/Expenses | 6.01M | -1.25M | -105.00K | -2.52M | -2.20M |
| Income Before Tax | 165.83M | 184.01M | 169.02M | 157.13M | 0.00 |
| Income Before Tax Ratio | 20.72% | 26.09% | 24.36% | 23.72% | 0.00% |
| Income Tax Expense | 35.17M | 37.27M | 36.25M | 33.59M | 0.00 |
| Net Income | 130.66M | 146.74M | 132.78M | 123.54M | 0.00 |
| Net Income Ratio | 16.32% | 20.80% | 19.14% | 18.65% | 0.00% |
| EPS | 5.04 | 6.01 | 5.46 | 5.35 | 0.00 |
| EPS Diluted | 4.99 | 5.93 | 5.21 | 5.16 | 0.00 |
| Weighted Avg Shares Out | 25.91M | 24.41M | 24.31M | 23.10M | 23.10M |
| Weighted Avg Shares Out (Dil) | 26.18M | 24.75M | 25.49M | 23.95M | 23.95M |
Source: https://incomestatements.info
Category: Stock Reports